March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Errors In Measuring VEGF Concentrations In The Presence Of Anti-VEGF Antibodies By Using ELISA
Author Affiliations & Notes
  • Hidenori Takahashi
    Ophthalmology, Tokyo KoseiNenkin Hospital, Tokyo, Japan
    Ophthalmology, University of Tokyo, Tokyo, Japan
  • Yujiro Fujino
    Ophthalmology, Tokyo KoseiNenkin Hospital, Tokyo, Japan
    Ophthalmology, University of Tokyo, Tokyo, Japan
  • Yasuo Yanagi
    Ophthalmology, University of Tokyo, Tokyo, Japan
  • Footnotes
    Commercial Relationships  Hidenori Takahashi, None; Yujiro Fujino, None; Yasuo Yanagi, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 6289. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hidenori Takahashi, Yujiro Fujino, Yasuo Yanagi; Errors In Measuring VEGF Concentrations In The Presence Of Anti-VEGF Antibodies By Using ELISA. Invest. Ophthalmol. Vis. Sci. 2012;53(14):6289.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Several reports have investigated the intraocular concentration of vascular endothelial growth factor (VEGF) after administration of anti-VEGF antibodies. Enzyme-linked immunosorbent assay (ELISA), which is widely used for measuring VEGF concentration, uses specific antibodies. Therefore, if anti-VEGF antibodies are already present in the samples, competition between these antibodies would introduce errors in measuring the concentration of VEGF in the samples. To confirm these hypothesis, we measured VEGF concentration in the presence of anti-VEGF antibody by using ELISA.

Methods: : We used the R & D Systems Quantikine Human VEGF ELISA kit (Minneapolis, MN, USA) for this study. Ranibizumab, bevacizumab, pegaptanib, and mouse control immunoglobulin G (IgG) were added to 1000, 500, 250, 125, 63, 31, 16, and 7.8 pg/ml VEGF. Using the previously investigated half-life of these compounds, we calculated the each antibody concentration in the vitreous cavity 28 days after the antibody injection, which showed that the concentration of ranibizumab, bevacizumab, pegaptanib, and IgG was calculated as 0.11, 13, 8.6, and 13 μg/ml respectively.

Results: : VEGF was measured at 540, 290, 120, 58, 29, 12, 6.4 pg/ml and undetectable in the presnce of ranibizumab. VEGF was measured at 31 and 10 pg/ml and undetectable from then on in bevacizumab group. VEGF was measured at 1000, 480, 230, 110, 55, 22, 11 pg/ml and undetectable in pegaptanib group. VEGF was measured at 1000, 650, 300, 150, 73, 32, 13, and 7.2 pg/ml in IgG group.

Conclusions: : The VEGF concentration measured by ELISA was lower than the total VEGF concentration when anti-VEGF antibodies were present. It was much lower when the antibodies had a low dissociation constant or when there was a high concentration of antibodies. Caution should be exercised when interpreting the VEGF concentration measured by ELISA in the presence of anti-VEGF antibody.

Keywords: vascular endothelial growth factor • drug toxicity/drug effects • age-related macular degeneration 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×